Trial Profile
Randomized, Double-blind, Euglycemic Glucose Clamp Study of Four Formulations of SAR161271, in Single Doses in Healthy Subjects and Single Ascending Doses in Patients With Type 1 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs SAR 161271 (Primary) ; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics
- 24 Nov 2010 Actual end date changed from May 2010 to Nov 2010 as reported by ClinicalTrials.gov.
- 15 Jun 2010 Actual patient number (46) added as reported by ClinicalTrials.gov.
- 15 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.